Free Trial

Haleon (HLN) Stock Forecast & Price Target

Haleon logo
$9.88 -0.57 (-5.41%)
Closing price 03:59 PM Eastern
Extended Trading
$9.99 +0.11 (+1.11%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
6
Buy
2

Based on 8 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 6 have given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for HLN.

Consensus Price Target

$10.95
10.77% Upside
According to the 8 analysts' twelve-month price targets for Haleon, the average price target is $10.95. The highest price target for HLN is $10.95, while the lowest price target for HLN is $10.95. The average price target represents a forecasted upside of 10.77% from the current price of $9.89.
Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

Sign Up

HLN Analyst Ratings Over Time

TypeCurrent Forecast
4/4/24 to 4/4/25
1 Month Ago
3/5/24 to 3/5/25
3 Months Ago
1/5/24 to 1/4/25
1 Year Ago
4/5/23 to 4/4/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.95$10.95$10.95N/A
Forecasted Upside10.77% Upside3.84% Upside15.75% UpsideN/A
Consensus Rating
Hold
Hold
Buy
Moderate Buy
Remove Ads

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Haleon Stock vs. The Competition

TypeHaleonMedical CompaniesS&P 500
Consensus Rating Score
2.38
2.81
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside10.77% Upside22,139.47% Upside32.37% Upside
News Sentiment Rating
Very Positive News

See Recent HLN News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/5/2025Hsbc Global Res
0 of 5 stars
J. Fialko
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/5/2025HSBC
2 of 5 stars
 Reiterated RatingBuy ➝ Hold
3/3/2025Deutsche Bank Aktiengesellschaft
3 of 5 stars
 Reiterated RatingHold ➝ Hold
1/10/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight
1/8/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Elliott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
10/1/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Delmas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/6/2024Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Davies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
8/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
O. Nicolai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
3/26/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy
8/8/2023Investec
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold
5/24/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:34 PM ET.


Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 2, 2025. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Haleon plc:

  • Haleon plc reported a revenue of $3.54 billion during the latest quarter, exceeding the consensus estimate of $3.38 billion, indicating strong financial performance and potential for growth.
  • The company has a return on equity of 14.76%, which suggests effective management and profitability relative to shareholders' equity, making it an attractive investment.
  • Haleon plc recently increased its dividend to $0.1166 per share, up from $0.05, reflecting a commitment to returning value to shareholders and a yield of 1.6%.
  • The current stock price is $10.30, which is near its 52-week high of $10.80, indicating positive market sentiment and potential for further appreciation.
  • Institutional investors own 6.67% of Haleon plc's stock, suggesting confidence from large financial entities in the company's future prospects.

Haleon
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Haleon plc for these reasons:

  • Despite the positive revenue report, the stock has a high P/E ratio of 30.28, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • Recent analyst ratings show a consensus rating of "Hold," with several brokerages downgrading their ratings, which may suggest a lack of strong bullish sentiment in the market.
  • The company has a beta of 0.25, indicating lower volatility compared to the market, which may limit potential high returns for investors seeking aggressive growth.
  • Haleon plc's net margin of 10.85% is relatively modest, which could indicate challenges in maintaining profitability in a competitive consumer healthcare market.
  • Institutional investors have recently adjusted their stakes, with some reducing their positions, which could signal caution regarding the company's future performance.

HLN Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is $10.95, with a high forecast of $10.95 and a low forecast of $10.95.

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last twelve months. There are currently 6 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLN, but not buy additional shares or sell existing shares.

According to analysts, Haleon's stock has a predicted upside of 10.77% based on their 12-month stock forecasts.

Over the previous 90 days, Haleon's stock had 3 downgrades by analysts.

Haleon has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Hsbc Global Res, HSBC, Morgan Stanley, and Sanford C. Bernstein in the past 90 days.

Analysts like Haleon less than other "medical" companies. The consensus rating for Haleon is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLN compares to other companies.


This page (NYSE:HLN) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners